Artist's rendering of Astellas' South San Francisco campus, set to open in 2023

Astel­las gath­ers scat­tered cell and gene ther­a­py, BD units in new $70M South San Fran­cis­co hub

Bring­ing all its West Coast-based units un­der one roof, Astel­las has un­veiled plans to pour $70 mil­lion in­to a new biotech cam­pus in South San Fran­cis­co.

With cell and gene ther­a­pies as the dom­i­nant theme, the Japan­ese phar­ma spot­light­ed Astel­las Gene Ther­a­pies and Xyphos Bio­sciences, which is de­vel­op­ing cell ther­a­pies for sol­id tu­mors, as the two big sub­sidiaries that will oc­cu­py the space. Those work­ing in the busi­ness de­vel­op­ment team and the Rx+ Busi­ness Ac­cel­er­a­tor are al­so set to move in with them.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.